Chimerix to present at JMP conference
Leading the presentation will be the chief medical officer for the company, Garrett Nichols, and it will be made available at the investor's relations page on the Chimerix website.
Recently the company has been involved in the development of the brincidofovir nucleotide analog lipid-conjugate that has shown to be an effective antiviral candidate for prominent dsDNA viruses, which include the pathogens behind the human adenovirus and smallpox.
Its use against the adenovirus is currently in the third phase of an AdVise trial. It is also being considered as an option for the treatment of cytomegalovirus in adult patients that previously had a hematopoietic cell transplant.
The company is also working with the Biomedical Advanced Research and Development Authority in order to develop efficacy against smallpox, a top level threat in terms of biological security.
Nichols will be presenting at the conference on June 24 beginning at 3 p.m. at the St. Regis Hotel in New York City.
The JMP Life Sciences conference brings publicly traded and privately held companies within biomedical, pharmaceutical and medical devices industries alongside others within the field of life sciences.